TANGO THERAPEUTICS, INC.
TNGXLoading price...
Overview
Previous Close--
Open--
Ask--
Bid--
Day's Range -
52 Week Range -
PE Ratio(TTM)--
Market Cap--
Volume--
Avg. Volume--
12 Months Earnings-107.23M
12 Months Revenue56.99M
Profit/Loss
| PARTICULARS | TTM | 2025 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Operating Revenue | 56.99M | 62.38M | 24.30M | 42.07M | 36.53M | 24.86M |
| Operating Expenses | 174.52M | 173.67M | 181.58M | 187.66M | 150.70M | 135.93M |
| Profit after Tax (Net Income) | -107.23M | -101.59M | -145.57M | -130.30M | -101.74M | -108.18M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: Boston, United States
Website: https://www.tangotx.com
Founder & Executive Chairman of the Board: Dr. Barbara L. Weber M.D.
Employees: 137
About Company:
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.